Posted on

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

Vancouver, British Columbia – November 9, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has filed a genetic neuroinflammatory disease patent which describes a  diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, including fragile X syndrome (FXS) and autism spectrum disorders (ASD).

“The ability to penetrate the unique genetic language underlying the development of neurodegenerative chronic diseases and assess therapeutic responses opens the door for the development of breakthrough products in the field of psychedelic medicine,” states Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “The clinical biomarker data generated with this genetic paradigm can be used to support the potential benefits of a psychedelic drug product IND application with U.S. FDA (1).”

  1. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Psychedelic music studio changes your attachment style: issue 22

Here’s what’s in store for you in today’s issue:

🍄 Psychedelic music studio receives $4.5M in funding

🍄 How your attachment style affects your trip

🍄 First-ever study with direct psilocin

🍄 A new helmet to understand the brain

🍄 And more.

Be sure to check out last week’s Daily Mushroom podcast:

The DMT Cure for Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

First-ever study with direct psilocin

When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most (or all) of the psychedelic effects.

Will the experience change if psilocin is administered directly?

Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.

The phase I trial at the University of California San Francisco will compare the effects of psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.

Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability — with fewer side effects.

A faster treatment for depressed moms

Existing treatments for post-partum depression take up to 8 weeks and often separate the mother from her baby for long periods of time, creating even more stress.

Field Trip Health (FTRP) is developing a proprietary psychedelic to change this.

The formulation, FT-104, could be administered in just one day and lasts 2-3 hours shorter than pure psilocybin. The compound leaves the mother’s system in just 24 hours, allowing her to safely breastfeed again.

FT-104 is currently in preclinical evaluation with phase I trials expected to begin in Q1 of next year.

atai accelerates schizophrenia research after promising findings

atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia.

The compound, RL-007, was tested on a cohort of 8 schizophrenic patients while continuing with their antipsychotic treatments. Using brain mapping and other biomarkers, researchers found that formulation improved cognition by activating receptors linked to learning and memory. 

The findings were so promising that atai decided to spend additional resources to accelerate the compound into a Phase 2a trial, which should be completed by the end of the year.

Ending the PTSD crisis

The lack of effective PTSD treatments is “a crisis,” according to the PTSD Psychopharmacology Working Group. About one in 20 people in the UK suffer from PTSD, and current treatment options are ineffective for 40% of patients.

COMPASS Pathways (CMPS) is launching a phase II trial to see if its psilocybin therapy model for treatment-resistant depression can bring relief to patients with PTSD.

The trial will assess 20 patients who experienced trauma as adults. They will be given a single dose of the psilocybin formulation followed by 12 weeks of therapy protocols.

Researchers will measure the safety of the drug as well as improvements in PTSD symptoms, functionality, and quality of life.

inspirational banner

Psychedelic music studio receives $4.5M in funding

When patients have a positive response to music during psychedelic therapy, they’re more likely to have a mystical experience which can lead to a more effective treatment.

That’s why neuroscientist Dr. Mendel Kaelen co-founded Wavepaths – a music studio that uses AI to create customized music—on the fly—in response to a patient’s emotional state!

The implications of Wavepaths go far beyond psychedelic therapy: hospitals, birth clinics, hospice centers, and schools are showing interest in the technology. It is already being used in 30+ countries and over 5,000 practitioners await its public release.

How your attachment style affects your trip

If you’ve ever struggled with attachment anxiety in your relationships, there’s promising evidence that psilocybin could be an effective treatment:

After undergoing individual therapy, group therapy, and a single psilocybin session, a group of 18 male AIDS survivors showed significantly reduced scores for attachment anxiety – an attachment style characterized by clinginess, fear of abandonment, and difficulty trusting others.

There were no significant changes in attachment avoidance, which is characterized by repressing emotions and discomfort with close relationships.

However, high attachment anxiety scores were associated with a greater chance of mystical experiences, whereas high attachment avoidance scores were linked to grief, fear, physical distress, and paranoia during the trip.

What better way to feel more secure in your relationships than through a trip? 🤩

Old Town Road to success

Lil Nas X was honoured as a visionary at the Wall Street Journal’s Innovator Awards after releasing his latest album, ‘Montero.’ Were magic mushrooms the secret behind his success?

The artist says that his first-ever mushroom trip was a pivotal moment while recording the album. The experience helped him reflect on himself and break free from feelings of self-consciousness.

“I was able to open up a lot. I was able to write actual stories about my life and put it into my music. I actually did that for the first time,” Nas explained.

business banner

A new helmet to understand the brain

The LA-based company Kernel developed a brain-imaging helmet that can track what actually happens in the brain during a psychedelic trip.

The device, Kernel Flow, was just approved by the FDA to be used in a ketamine trial sponsored by Cybin (CYBN).

Researchers will use the helmet to measure the neurological activity of 15 patients during a ketamine therapy session compared to baseline activity.

Kernel Flow is much less expensive than other brain-imaging tools and allows the patients to move freely during the session.

Trip at home with a psychedelic patch

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

Creating a myriad of drugs with AI

Using an AI drug discovery program, Mydecine (MYCO) successfully added a novel psilocin analogue with improved delivery and stability to its pipeline.

The AI technology synthesizes billions of drug candidates and filters them based on psychedelic-related targets such as how they bind to receptors.

Mydecine also filed a patent for nanoemulsion technology. Nanoemulsion can:

  • help the company develop compounds inspired by traditional plant medicines such as reishi and cordyceps mushrooms
  • improve control in delivery, which is critical in microdosing and customizing dosages
  • advance development of over-the-counter consumer products
legal banner

Detroit decriminalizes psychedelics!

With a 61% to 39% win, Detroit became the fourth city in Michigan to widely decriminalize possession and therapeutic use of psychedelics.

Over 80% voted to establish a reparations committee that will address historical discrimination against Black communities through housing and economic development programs.

Industry Quick Hits

Oct 29 – Oppenheimer initiates COMPASS Pathways (CMPS) with a buy rating and $50 price target Read more…

Oct 29 – Braxia Scientific (BRAX) Announces Voting Results from the Annual General Meeting of Shareholders Read more…

Nov 1 – Blackhawk Growth’s (BLR) MindBio Therapeutics Looks to Expand Microdosing Clinical Trials Read more…

Nov 1 – Algernon Pharmaceuticals (AGN) reports positive pre-clinical data on DMT candidate to treat stroke Read more…

Nov 1 – Small Pharma (DMT) reports second quarter highlights Read more…

Nov 2 – Braxia Scientific (BRAX) Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program Read more… 

Nov 2 – U.S. FDA Approves Nova Mentis (NOVA) Orphan Drug Application Read more…

Nov 2 – Tryp Therapeutics (TRYP) Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia Read more…

Nov 3 – Amanita Muscaria Mushroom Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Read more…

Nov 4 – Awakn Life Sciences (AWKN) Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry Read more…

Nov 5 – Novamind (NM) Reports FY2021 Financial Results and Operating Highlights Read more…

Nov 5 – NeonMind (NEON) Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine Read more…

Video of the Week

Trippy Mushroom-Themed Resort

Playlist of the Week

60s - 70s stoner rock
Posted on

Nova Mentis to Present at the Wonderland: Miami Psychedelic Conference

Nova Mentis to Present at the Wonderland: Miami Psychedelic Conference

Vancouver, British Columbia – November 4, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will present at  Microdose’s Wonderland: Miami psychedelic conference, from November 8-9, 2021.

Dr. Marvin S. Hausman, MD, Chairman of NOVA’s Scientific Advisory Board, will discuss the company’s significant psilocybin drug development breakthroughs in its preclinical models of autism and fragile X syndrome, and how being the first biotech company to receive psilocybin orphan drug designation in the U.S. and European Union will assist the company on the pathway to drug approval.

“Psychedelic medicine is offering much promise as a new therapeutic paradigm with the potential to provide much needed treatment options, especially in areas with unmet medical needs. The ability to penetrate the unique genetic language underlying the development of chronic diseases and assess therapeutic responses will assist in obtaining psychedelic drug approval with the regulatory agencies.”

Dr. Hausman will be presenting on the Psychedelics and New Paradigms panel, which takes place on Tuesday, November 9 from 3:00pm-3:35pm.

Wonderland: Miami is the largest ever psychedelic medicine business event and is being organized by Microdose.


About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

 

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

U.S. FDA Approves Nova Mentis Orphan Drug Application

U.S. FDA Approves Nova Mentis Orphan Drug Application

Psilocybin Fragile X Syndrome Treatment

Vancouver, British Columbia – November 2, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that the U.S. FDA has approved the Company’s proprietary psilocybin drug Orphan Drug Application to  treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).

“NOVA has established a unique position in the field of psychedelic therapy by having its FXS program achieve orphan drug status in both the United States and European Union,”says Will Rascan, NOVA’s CEO & President. “I am pleased to announce that we are the first biotech company to have psilocybin registered for treatment of FXS in the drug regulatory logs of both the FDA and EMA.”

Medicines that have been granted an orphan designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) receive  benefits, including but not limited to:

  • Seven-Ten years of market exclusivity: FDA and EMA cannot approve the same drug for the same indication.
  • 25% federal tax credit for expenses incurred in conducting clinical research within the United States.
  • Waiver of Prescription Drug User Fee Act (PDUFA) fees: a value of approximately $2.9 million.
  • Ability to qualify to compete for research grants from the Office of Orphan Products Development (OOPD) to support clinical studies.
  • Eligibility to receive regulatory assistance and guidance from the FDA in the design of an overall drug development plan.

“The attainment of Orphan Drug status in both the U.S. and Europe is a significant milestone towards launch of psilocybin FXS phase 2 clinical studies,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “The U.S. FDA has issued guidance concerning the usage of observational clinical study Real-World Evidence (RWE) to support the potential benefits of a medical product (1).  NOVA intends to immediately launch an IRB approved ASD observational study to provide baseline clinical biomarker RWE data in support of its psilocybin IND to treat FXS.”

  1. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

A better way to get drunk: issue 21

Here’s what’s in store for you in today’s issue:

🍄 The future of psychedelics, according to an expert

🍄 A better way to get drunk

🍄 A first-of-its-kind severe anxiety study

🍄 The race for a dementia treatment

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

The DMT Cure to Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

A better way to get drunk

This psychedelic makes you feel drunk. Could it be used to treat alcoholism?

5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.

Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials are expected to begin in the second half of 2022. 

The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.

First-of-its-kind study on severe anxiety

Monash University just got the go-ahead to conduct a first-of-its-kind study!

Yesterday, the Australian university received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).

Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).

The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.

Does neuroplasticity benefit healthy people too?

Psychedelics clearly have a huge impact on people with mental health issues, but how do they impact people who are already mentally healthy? A new research project at University College London will give us more insights!

After two years of planning, the university is launching the “Understanding Neuroplasticity Induced by Tryptamines” or UNITy Project.

UNITy Project will use fMRI scans, eye-tracking, and experience sampling to understand how the naturally functioning brain responds to various tryptamines (psychedelics that bind to serotonin receptors, such as psilocybin).

The first study will evaluate how DMT affects language processing, sensory processing, and memory in both healthy participants and heavy drinkers, and if neuroplasticity drives the results.

inspirational banner

The future of psychedelics, according to this pioneering researcher

Rick Doblin, a pioneering psychedelic researcher and activist, made some interesting predictions about the future of psychedelics in the US:

  • MDMA will be FDA-approved by the end of 2023, with psilocybin following a year or two after.
  • By 2023 or 2024, there will be 6000+ psychedelic therapy clinics (there are currently about 1000). Every town with a hospice center will have enough demand for a psychedelic clinic.
  • By 2030, one million MDMA therapy sessions will have been administered by 25,000 trained therapists.
  • A licensed legalization model could be implemented around 2035 in which patients can earn a license to use psychedelics outside the clinic once undergoing a supervised session.

Doblin is hopeful that the tremendous impacts on mental health will result in a spiritualized society that “has finally come to the point of embracing global thinking, global humanity, and dealt with economic inequity.”

Donation heals traumatized children

“We’re all traumatized children running around in adult bodies, and (psychedelic) medicines can help us all,” according to venture capitalist Sanjay Singhal.

That’s why his charity donated $5 million to launch The Nikean Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN).

The centre will study psilocybin therapy as a treatment for terminally-ill patients, patients with body dysmorphia, families who have lost a child, and grieving caregivers. It will also study 5-MeO-DMT as a PTSD treatment and will train therapists to administer psychedelic therapy.

Singhal, who was diagnosed with bipolar disorder in his 30s, was inspired to fund psychedelic research after a psilocybin trip helped him break down his emotional walls and fix his relationships.

Can shrooms make you a better leader?

Magic mushrooms may have been the key to this NHL legend’s success.

Mark Messier, the only NHL player to lead two different teams to Stanley Cup championships, said that a magic mushroom trip at age 19 sparked his interest in spirituality and the power of the mind.

“I had no idea the mind was that powerful. Obviously it turned out to be an amazing experience, but more important was the question afterwards: wow, how can I use my mind to empower myself to be a better player, to be a better person, to have more energy, to create a better aura?”

The trip inspired Messier to learn about Eastern philosophies, Buddhism, Indigenous spirituality, and meditation, which had a major influence on him both as a player and a leader.

business banner

Tripping on an island to help frontline workers

Cybin (CYBN) is sending therapists on a psychedelic retreat so they can learn how to provide support to frontline healthcare workers.

Clinical trial facilitators will head to a small island in Washington to be trained on Cybin’s new EMBARK therapy model and gain experiential knowledge of psychedelics. The EMBARK model combines aspects of several psychotherapy models and incorporates patients’ spiritual experiences, bodily experiences, and relationships into the healing process.

The retreat will prepare the facilitators for an upcoming clinical trial at the University of Washington that aims to treat healthcare workers suffering from COVID-related distress, depression, anxiety, and PTSD.

Optimizing the DNA of plant medicines 

Delic Labs of Delic Corp (DELC) is partnering with GT Research Inc. to help mushroom and cannabis producers optimize their products. 

Through the deal, Delic Labs will use DNA analysis to evaluate the commercial value of different cannabis and psychedelic mushroom strains based on certain gene traits. The services will help Canadian producers optimize their compounds through genetic engineering to produce more effective plant medicines.

Which company will develop a dementia treatment first?

If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050 — reaching $1.1 trillion in care costs.

Fortunately, two more companies joined the race to develop a new treatment using psychedelics!

On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.

Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.

Researching ADHD treatments in Korea

These companies are joining forces to develop unique treatments for a range of debilitating conditions.

Agtech Global International Inc. (AGGL) and  KRTL Biotech Inc. are partnering to develop CBD and psilocybin-based medicines to treat conditions like ADHD, pain from cancer, autism, PTSD, depression, and addiction.

The agreement will leverage KRTL’s team of researchers in the US and Korea, where they have already received the Korean equivalent of FDA approval to study the compounds.

Several other companies are supporting the research project including Here To Serve Holding Corp. (HTSC) and Pervasip Corp. (PVSP).

legal banner

Here’s what you missed:

  • Next Tuesday, Detroit will vote on a bill to decriminalize possession and therapeutic use of entheogens including psilocybin mushrooms, ayahuasca, and peyote. Read more…
  • A DC non-profit called The Plant Medicine Coalition issued $50K in grants to community organizations that promote psychedelic education and reform thanks to donations from Dr. Bronner’s soap company. Read more…
  • Dr. Bronner’s is also funding a lobbyist group that’s working to legalize psilocybin for therapeutic uses in Connecticut. Read more…

Industry Quick Hits

Oct 25 – HAVN Life (HAVN) Announces Departure Of Rick Brar As Director Read more…

Oct 26 – Nova Mentis (NOVA) Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome Read more…

Oct 27 – Mindset Pharma (MSET) Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Read more…

Oct 27 – PharmaTher (PHRM) Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022 Read more…

Oct 28 – Blackhawk Growth’s (BLR) Subsidiary MindBio Therapeutics Appoints Patrick Moher as Advisor Read more…

Oct 28 – Greenbrook TMS (GTMS) Announces Dates For Its Third Quarter 2021 Financial Results Read more… 

Oct 28 – MYND Life Sciences (MYND) Announces Appointment of New Director Read more…

Oct 29 – Blackhawk Growth (BLR) Files Fiscal Year Ended June 30, 2021 Financial Reports Read more…

Video of the Week

Trip with your breath: Intro to holotropic breathwork

Playlist of the Week

Lo-Fi | psychedleia
jack O' lantern mushroom
Posted on

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Vancouver, British Columbia – October 26, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received orphan drug designation from the European Medicines Agency (EMA) for its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the leading genetic cause of symptoms related to autism spectrum disorder (ASD).

“Orphan Drug designation of our proprietary psilocybin formulation in Europe is a significant milestone on the pathway to drug approval,” says Will Rascan, NOVA’s CEO & President. “This achievement has the potential to rapidly advance our company’s clinical program in Europe with the goal of approval of psilocybin in the treatment of FXS, a major unmet medical need. Nova intends to move expeditiously to begin a phase 2 study with psilocybin in FXS.” Medicines that have been granted an orphan designation receive the following benefits:

  • Ten years of market exclusivity: once approved, NOVA’s proprietary formulation is protected from competition with similar medicines in similar indications.
  • Reduced fees for protocol assistance and other regulatory activities.
  • Access to grants from the European Commission and other sources.
  • Scientific advice and administrative and procedural assistance.
  • Access to a centralized marketing authorization with a single application.

There are currently no approved prevention or treatment methods for FXS. Current therapies, including pharmaceutical and behavioural interventions, offer a patchwork of solutions that have limited efficacy and high toxicity. Psilocybin has the capacity to influence cognition and behaviour as well as modulate the immune system and neural signaling pathways. Likewise, psilocybin is non-toxic and is not expected to have adverse side effects in humans.

“Our proprietary psilocybin drug is being proposed as a novel, first-in-class treatment for fragile X,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. We have achieved several drug development breakthroughs this year, including a significant therapeutic effect in validated preclinical models of ASD and FXS, identification of an effective dose and no observed psilocybin toxicity. We look forward to working closely with EMA to advance our efforts to receive European regulatory marketing approval for our leading psilocybin drug candidate.”

EMA is a decentralised agency of the EU responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. Orphan designation is a status assigned to a medicine intended for use against a rare condition.

 

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

 

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Autistic children try microdosing at a psychedelic farmer’s market: issue 20

Here’s what’s in store for you in today’s issue:

🍄Autistic children try microdosing

🍄 Group psychedelic therapy cures depression

🍄 Psychedelic farmer’s markets?

🍄 DMT granted innovative medicine designation

🍄 And more.

You’ll want to stay till the end to learn how someone found enlightenment on a trippy hike.

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
The Truth About Psilocybin and the Brain

Julia Joyes is a neuroscientist and research director at TheraPsil, a leading non profit organization making a difference to mental health in Canada. In this episode, we take a closer look at psilocybin’s impact on the brain. 

Therapeutic banner

The first study investigating psilocybin’s impact on children

According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.

Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to deliver a self-administered and non-invasive microdose.

The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism, including pediatric patients. This will be the first study investigating psilocybin’s impact on children.

Group psychedelic therapy cures depression!

On Tuesday, Compass Pathways (CMPS) received a US patent for COMP360, its proprietary formulation of crystalline psilocybin. On Wednesday, the company announced positive findings from an open-label study using the formulation to treat depression in cancer patients.

Thirty patients were administered COMP360 in group therapy sessions of two to four people. Twenty-four people experienced at least a 50% reduction in depression symptoms within three weeks of treatment, which was sustained at week eight, and fifteen people were in total remission from depression.

The average depression score dropped from 25.9 to just 6.8!

The company notes that the study was not blinded or placebo-controlled, so the findings are subject to expectancy bias, but the results show promise that both COMP360 and group therapy models are effective.

Trip your way to a healthier lifestyle

Psychedelics improve mental health, but can that translate into better physical health too?

A recent study found that people who have tried psychedelics at least once in their life had a 23% lower chance of heart disease and a 12% lower chance of diabetes in the past year.

Other research indicates that psychedelic use is tied to healthier lifestyle choices such as increased exercise, reduced smoking and alcohol consumption, and a balanced diet.

Researchers also theorize that psychedelics could stimulate brain receptors that are linked to both mental and cardiometabolic health.

inspirational banner

DMT receives innovative medicine designation

DMT-assisted therapy could be approved in the UK sooner than expected!

Yesterday, Small Pharma (DMT) received an Innovation Passport Designation for its DMT-assisted therapy program for depression – a status given to promising medicines to expedite development. The passport gives the company access to the Innovative Licensing and Access Pathway (ILAP) to reduce time to market and facilitate patient access to the treatment.

The designation is essentially the UK’s version of a Breakthrough Therapy Designation, which the FDA granted to Compass Pathways (CMPS) and Usona Institute in 2018 and 2019, respectively, for their psilocybin-assisted therapy programs.

Small Pharma also launched a Phase 2a clinical trial for DMT-assisted therapy on Tuesday and began trading on the OTCQB market on Wednesday under the symbol “DMTTF”.

The largest psychedelic event in history

Curious about the latest advancements in psychedelic medicine, psychedelic retreats, microdosing, or the role of technology in the psychedelics sector? Then you won’t want to miss Microdose HQ’s Wonderland: Miami – the largest psychedelic medicine business event to date!

The two-day event on Nov. 8-9 will have keynote presentations from some of the biggest names in the psychedelic sector including including Robin Carhart-Harris, Matthew W. Johnson, Rick Doblin, and David Nutt.

(Mike Tyson and Lamar Odon will also share their experiences with psychedelic healing!)

The speakers will cover a vast range of unique topics: 

  • Shamanic protocols for making investment decisions…
  • Psychedelics and sports…
  • The threat of corporate domination in the industry…
  • And more.

Get your your ticket or virtual access pass here!

business banner

Be an early investor 🤑

Want to be an early investor in a psychedelics company? Now’s your chance!

Ei.Ventures is currently looking to raise $50M through a Regulation A+ Framework – a type of offering that allows the general public, not just institutional or accredited investors, to buy shares in a company before it goes public.

“I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies,” said David Nikzad, the company’s founder, who was an early investor in Airbnb , Betterment, and Vidyard.

Ei.Ventures is developing a transdermal psilocybin patch and is preparing to launch a functional mushroom line early next year. Shares are selling for $4.94 each with a minimum purchase of 101 shares, and the company has already raised $20M. Take advantage of the offer here.

The world’s biggest psychedelic therapy provider

Field Trip Health (FTRP) just got one step closer to reaching its goal of running 75 psychedelic therapy clinics by 2024.

The company opened three new treatment centers in Seattle, Vancouver and Fredericton. It now administers ketamine-assisted therapy at eight clinics across North America and one in Amsterdam.

The treatment is proving to be effective with clients’ depression scores dropping from an average of 17 (severe) to 6 (mild) and benefits lasting at least 120 days.

74 studies on 50 compounds 🤯

This week, Cybin Inc. (CYBN) completed its 74th preclinical study to advance its proprietary molecules, CYB003 and CYB004, toward clinical research.

The company has evaluated 50 novel compounds in its preclinical research, narrowing it down to four lead candidates. including CYB003 for alcohol use disorder and CYB004 for anxiety disorders.

Compared to classic psychedelics, the formulations are showing:

  • Faster onset times
  • Shorter durations
  • High oral bioavailability
  • Significant brain penetration, and
  • Less variability between subjects

Human clinical trials are expected to begin early next year to work toward an Investigational New Drug (IND) status.

legal banner

Psychedelic farmer’s markets coming to Cali!

Oakland could legalize the sale of psychedelics as early as next year!

The city decriminalized the use and cultivation of many psychedelics back in 2019, and now, activists are building on their progress with a “Go Local” Legislative Initiative. The initiative would create a community-based model to allow people to legally purchase natural psychedelics like psilocybin and ayahuasca from local producers.

The initiative will gather research on how best to implement the model over the next year and will introduce a legislation in the summer of 2022.

Some possible reforms being considered include allowing commercial agriculture in residential zones, creating “sacred plant adult farmer’s market permits,” and allowing cannabis dispensaries with 100% local ownership to sell entheogens, among many others.

All products would have to be grown, produced, and tested locally.

Another unanimous win 🎉

After yet another unanimous vote, Easthampton became the fourth city in Massachusetts to decriminalize possession and cultivation of psychedelics!

Will this European island legalize shrooms?

Malta may legalize cannabis, but residents don’t want the reforms to stop there.

In a recent survey, 447 people in Malta were asked if they think the country should legalize any other substances beyond cannabis. Magic mushrooms was the most popular response with 45% in favour of its legalization.

LSD was the next most common response at 27%, but 56% did not see a need for any other drugs to be legalized.

Industry Quick Hits

Oct 18 – Johns Hopkins Receives $4M from the NIH – The First Federal Grant for Psychedelic Research in 50 years Read more…

Oct 19 – FSD Pharma (HUGE) Signs Agreement With Covar Pharmaceuticals To Support The Development Of Lucid-Psych Read more…

Oct 19 – Psyched Wellness (PSYC) says preliminary data reveals potential new functional property of Amanita mushroom for treating skin conditions Read more…

Oct 19 – Bank Of America Shuts Down Account Of Cannabis & Psychedelics Research Institute Registered With DEA Read more…

Oct 19 – atai Life Sciences (ATAI) Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change Read more…

Oct 20 – Tryp Therapeutics (TRYP) Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders Read more… 

Oct 20 – LOVE Pharma (LUV) Announces Development of Muco-Adhesive Sublingual Psilocybin Strip Read more…

Oct 21 – Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific (BRAX) CEO Dr. Roger McIntyre Read more…

Oct 22 – Novamind (NM) Unveils Stealth Mode Investment in Alto Neuroscience Read more…

Video of the Week

Dr. Bronner’s Support for Psychedelic-Assisted Therapy and Plant Medicines

Playlist of the Week

Lo-Fi | psychedleia
mushrooms on scale
Posted on

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders

October 19, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, and Mycrodose Therapeutics (“Mycrodose”), a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announce that they have entered into a letter of intent (“LOI”) to develop patented products to treat neuroinflammatory disorders, such as fragile X syndrome (“FXS”) and autism spectrum disorder (“ASD”).

The Joint Venture (“NewCo”) will accelerate the research and development of psilocybin-based therapeutics by utilizing Mycrodose Therapeutics’ patented advanced drug delivery systems with Nova’s proprietary psilocybin drug to treat patients with neuroinflammatory conditions, including FXS, the most common inherited cause of ASD.

“NOVA’s lead drug candidate, psilocybin, has revealed significant promising results in preclinical models of fragile X syndrome and autism spectrum disorder. The results are exciting and have shown that psilocybin corrects the cognitive deficits displayed by a rat model of FXS and mitigates the anxiety-like traits observed in an environmental model of autism based on prenatal exposure to valproic acid,” stated Marvin S. Hausman MD,  Chairman of NOVA’s Scientific Advisory Board. “We have established a microdose therapeutic level for psilocybin in our most recent study that can be used in a planned upcoming human clinical study. This collaboration with Mycrodose Therapeutics is a ‘hand and glove fit’ with our breakthrough psilocybin microdose discovery, as their advanced drug delivery technologies offer many advantages for microdosing drug delivery, including providing a non-invasive, sustained and controlled dose of medicine that can be self-administered.”

NOVA has already successfully completed four preclinical studies confirming the therapeutic efficacy of the company’s proprietary psilocybin drug. The ability of the drug to modulate levels of neuroinflammatory molecules (cytokines) measured pre- and post-treatment is an important catalyst driving the fragile X clinical program.

“With the high safety profile of Mycrodose’s technologies and NOVA’s FDA/EU FXS orphan drug indication for its proprietary psilocybin, this partnership opens microdosing psilocybin-based drugs to a broader patient base, including pediatric applications. To our knowledge, the planned therapeutic study for autism and fragile X will be the first to research the potential for psilocybin to help treat pediatric patients,” says Chad Conner, Chief Executive Officer, Mycrodose Therapeutics. “The complementary relationship between NOVA and Mycrodose definitely helps everyone get into clinical trials faster with fewer hurdles. The sum of this partnership with NOVA is much greater together than each individual company alone, and allows our combined team to deepen its research on our kids and young people, a segment of the population that truly touches all of our hearts.”

NOVA has applied to the US FDA and European Union for psilocybin Orphan Drug designation for fragile X syndrome treatment, which would provide a wide range of financial and regulatory benefits.

The US Orphan Drug Act grants very attractive financial incentives to companies through a seven-year period of market exclusivity for the drug approved, even if the product is not under a provisional or granted patent. In addition, the US Orphan Drug Act provides tax credits of up to 50% of the qualified clinical testing expenses, provides grants for clinical testing, additional assistance in framing protocols for investigations, and the FDA waives the $2.4 million New Drug Application filing fee.

Summary Terms of the LOI include:

  • The Parties will incorporate a company (“NewCo“) whereby both Nova Mentis and Mycrodose Therapeutics will subscribe for shares to become equal 50% shareholders of NewCo and nominate an equal number of individuals to the Board of Directors of NewCo.
  • NewCo will be the owner of the Product(s), technologies, R&D protocols, and data gathered.
  • The Parties will mutually develop a R&D and Clinical Plan.
  • Mycrodose Therapeutics will give an exclusive license of its patented technologies to the collaboration for agreed upon indications.
  • A Scientific Advisory Board (“SAB”) will be created by the Parties to decide priorities based on rationales (financial, medical, clinical, scientific, delivery, etc.) that ranks the importance of specific product development and applicable clinical programs. The formalization of a definitive agreement is subject to satisfactory due diligence from both parties as well as other conditions customary for such a transaction.

About Mycrodose Therapeutics

Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

For more information about Mycrodose Therapeutics, please contact:

Patrick Eckstrom

Chief Operating Officer

Mycrodose Therapeutics

Email: Patrick@MycrodoseThera.com

Phone: 1-619-494-1367

Website: www.MycrodoseThera.com

 

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please

visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board

Will Rascan, President & CEO

Nova Mentis Life Science Corp.

Phone: 778-819-0244

Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

 This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Autistic children try microdosing

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.

Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to self-administer a non-invasive microdose.

The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism spectrum disorder (ASD), including pediatric patients. This will be the first study investigating psilocybin’s impact on children.

PDF of article

Posted on

Educated young adults are taking more psychedelics and drinking less: issue 15

Here’s what’s in store for you in today’s issue:

🍄 A different approach to treating depression

🍄 6 stocks to make you $

🍄 Healing racial trauma

🍄 A new psychedelics ETF

🍄 And more.

You’ll want to stay till the end to learn how someone travelled to different dimensions with Post Malone!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast!
How Psilocybin Is Revolutionizing The Way We Die

In this episode Natasha Fearnley, the first nurse to legally experience psilocybin therapy, shares her fascinating views on palliative care.

Therapeutic banner

Can this combination treat depression?

Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.

The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.

Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.

The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).

Healing racial trauma

A mission to end racism, bring equity to healthcare, and treat racial trauma. Psychologist, Monnica Williams of the University of Ottawa, believes that psilocybin and MDMA can help people of colour address the trauma they’ve endured from racial biases.

“Using psychedelics can not only bring these pain points to the surface for healing, but can reduce the anxiety or response to these memories and allow them to speak openly about them without the pain they bring,” Williams says.

She notes that POC are vastly underrepresented in the mental health care sector, specifically in psychedelic-assisted therapy, and expresses the need for specialized training to work with marginalized groups.

Williams has struggled to find funding for her research in this area in the past, but she’s hopeful that her work will gain more traction with the recent increased attention to racial justice.

Tapping into traditional healing

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

inspirational banner

Educated young adults are taking more drugs and drinking less

To escape the boredom and stress of the pandemic, college students are turning to psychedelics and marijuana.

A recent study found that psychedelic drug use among college students nearly doubled during the pandemic, increasing from 5% in 2019 to 9% in 2020. For non-college young adults, use increased from 8% to 10%.

College students also reported record-high marijuana use and record-low levels of alcohol consumption and binge drinking, likely as a result of fewer social events.

Experts predict that these trends reflect need to cope with mental health issues the desire to break monotony with a different mental state.

Psychedelic journalists!

“As the field of psychedelics explodes, we’re going to need sophisticated journalism to provide the public with reliable information and the field with accountability.”

That’s where Tim Ferriss steps in.

His non-profit organization, the Saisei Foundation, just donated $800,000 over three years to UC Berkeley’s Center for the Science of Psychedelics (BCSP) to establish the Ferriss – UC Berkeley Psychedelic Journalism Fellowship.

The fellowship, which will be overseen by BCSP co-founder Michael Pollan, will support young journalists reporting on the psychedelics industry for mainstream news outlets. Journalists can apply to receive grants of up to $15,000 to investigate the science, policy, business and culture of psychedelics.

business banner

These 6 stocks will make you money 🤑

On Tuesday, the Canadian investment bank Eight Capital gave a Buy rating to 6 psychedelic stocks. Here are the projected returns:

Invest in this ETF… because YOLO 😉

New ETF alert!

Yesterday, AdvisorShares launched the first psychedelic ETF on a US exchange – NYSE: PSIL.

The portfolio manager, Dan Ahrens, has an extensive track record of managing ETFs in a variety of sectors including two cannabis ETFs, MSOS and YOLO.

The distribution of holdings is shown below:

legal banner

Michigan paves the way

Michigan could be the next state to decriminalize psilocybin!

Senator Jeff Irwin (D-Ann Arbor) introduced a bill, SB 631, that would decriminalize the use, possession, cultivation, and delivery of psilocybin and mescaline.

The bill would also allow practitioners to use the psychedelics in counseling or spiritual guidance, but commercial sales would remain illegal.

The city of Ann Arbor, Michigan has already decriminalized psychedelics, and Detroit isn’t far behind with a decriminalization initiative to appear on the ballot this November.

Go sign this petition!

A California activist group, Decriminalize California, is working to get a psilocybin legalization measure on the 2022 ballot, and they’re making progress!

The measure, called the California Psilocybin Initiative, would allow the possession, use, cultivation, social sharing, and even the retail sale of psilocybin.

This week, the group was  cleared to begin collecting signatures for the initiative- they’ll need 623,212 registered voters to sign the petition within 180 days. Luckily, 2,800 people have already volunteered to help with the process.

“I feel pretty damn good honestly [about the prospects of the initiative]. People are so psyched for psychedelics,” said the director of the campaign.

Industry Quick Hits

Sept 14 – Nova Mentis (NOVA) Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment Read more…

Sept 14 – First subject dosed in Beckley Psytech’s psilocybin trial for rare headache disorder Read more…

Sept 14 – Mindset Pharma (MSET) Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay Read more…

Sept 17 – Enveric Biosciences (ENVB) Announces Closing of MagicMed Industries Acquisition Read more…

Video of the Week

Expert Answers Psychedelics Questions From Twitter (ft. Michael Pollan)

Seeing aliens with Post Malone

This Reddit user tapped into different dimensions after taking 2.7 grams of Penis Envy mushrooms.

“I turned on a podcast that I highly recommend to all experienced trippers after my experience with it. It was Joe Rogan and Post Malone tripping together. Once I turned on the podcast I was immediately intrigued about how I could feel their emotions and vibes and feel like I was tripping with them. All of the sudden my no-visual trip got slapped in the face when the whole tv starting started to swirl around and their eyes got all geeked out. I was about to turn it off because I didn’t want to have a artificial video of edited psilocybin visuals. I paused the video, and I realized that the screen was still moving like it was before and the visuals were REAL. At that moment in time I got excited because I knew what was about to come was gonna be good.

I turn the podcast back on and I start to zone out at the tv when I feel a rush of euphoria flowing though my body at the beat of my heart. I was manually breathing and I felt like I was gonna fall FORWARD while laying down because the end of my bed was a for some reason interrupted as a cliff my my brain. The whole room was a weird color like a color invert Instagram filter, I don’t know how to explain this in words guys, but I actually felt like I was being lifted and about to be thrown off my bed. I was gripping for dear life my god it was intense.

Then they started taking about aliens.. they said something about them being around all the time but we just can’t see them until we’re on mushrooms. BOOM fucking blast off I was seeing my own version of alien entity’s all around me. Every square inch of my peripheral vision was different species staring at me. It was incredible.

But I’d like to mention, only watch this podcast if you’re experienced because they do talk about ghosts and the most terrifying things they can think of at one point and they actually scared themselves a little bit lol. Creeped me out too because it wasn’t just stories, I FELT the ghosts and spirits. With full force I was like a skipping record player switching through dimensions on every topic they’d talk about and I felt like Post Malone was family for about three hours. I have never been so deep in my life and this is the most excited I’ve ever been about mushrooms and their capabilities of tapping into other worlds and dimensions and having realizations that you can’t EVER have sober.”

Playlist of the Week

Trippy Trance 👽
fishing for a mushroom